4-(4-Fluorophenyl)piperidine-4-carboxylic acid | 752982-57-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-Fluorophenyl)piperidine-4-carboxylic acid
• CAS: 752982-57-3
• 化学式: C₁₂H₁₄FNO₂
• 分子量: 223.24
• InChiKey: QFHFMHREPUBQBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Emonds-Alt Xavier

  公开号：US20070142349A1

  公开（公告）日：2007-06-21

  The invention relates to compounds corresponding to formula (I): in which: Ar represents a mono- or disubstituted phenyl; R 1 represents an unsubstituted or substituted phenyl; R 2 represents: a pyridyl; an unsubstituted or substituted phenyl; a benzyl that is unsubstituted or substituted on the phenyl; R 2 may moreover represent: a heterocyclic radical; R 3 represents various values. The invention also comprises methods for the compounds preparation, formulations comprising them and therapeutic applications thereof.

  这项发明涉及与以下式（I）对应的化合物： 其中：Ar代表单取代或双取代的苯基； R1代表未取代或取代的苯基； R2代表：吡啶基；未取代或取代的苯基；苯基上未取代或取代的苄基； R2还可以代表：杂环基； R3代表各种值。该发明还包括所述化合物的制备方法、包含它们的配方以及它们的治疗应用。
• [EN] PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE COMME ANTAGONISTES DE RÉCEPTEUR DE NK3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010106081A1

  公开（公告）日：2010-09-23

  The present application relates to compounds of formula (I) wherein the definitions are as described in claim 1. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本申请涉及式(I)的化合物，其中定义如权利要求1所述。已发现这些化合物是治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• Chemical compounds
  申请人：Alvaro Giuseppe

  公开号：US20060128752A1

  公开（公告）日：2006-06-15

  The present invention relates to cyclic amine derivatives of formula(l) wherein R represents halogen, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; R 1 represents hydrogen, halogen, C 3-7 cycloalkyl, hydroxy, nitro, cyano or C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 represents hydrogen or C 1-4 alkyl; R 3 and R 4 independently represent hydrogen, cyano, C 1-4 alkyl or R 3 together with R 4 represents C 3-7 cycloalkyl; R 5 represents trifluoromethyl, S(O) t C 1-4 alkyl, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, halogen or cyano; R 6 represents hydrogen or (CH 2 )rR 7 ; R 7 represents hydrogen, C 3 7 cycloalkyl, NH(C 1-4 alkylOC 1-4 alkoxy), NH(C 1-4 alkyl), N(C 1-4 alkyl) 2 , OC(O)NR 9 R 8 , NR 8 C(O)R 9 or C(O)NR 9 R 8 ; R 9 and R 8 independently represent hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m represents zero or an integer from 1 to 4; n represents 1 or 2; p is zero or an integer from 1 to 3; q is an integer from 1 to 3; r is an integer from 1 to 4; t is 0, 1 or 2; provided that when m is 0, p is 2, q , r and n represent 1, R 1 , R 2 ,R 3 , R 4 , R 5 and R 7 are hydrogen and R is chlorine, R 5 is not iodine; and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tackykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  本发明涉及式（I）的环状胺衍生物，其中R代表卤素、C1-4烷基、氰基、C1-4烷氧基、三氟甲基或三氟甲氧基；R1代表氢、卤素、C3-7环烷基、羟基、硝基、氰基或C1-4烷基，可选地被卤素、氰基或C1-4烷氧基取代；R2代表氢或C1-4烷基；R3和R4独立地代表氢、氰基、C1-4烷基或R3和R4一起代表C3-7环烷基；R5代表三氟甲基、S（O）tC1-4烷基、C1-4烷基、C1-4烷氧基、三氟甲氧基、卤素或氰基；R6代表氢或（CH2）rR7；R7代表氢、C37环烷基、NH（C1-4烷基OC1-4烷氧基）、NH（C1-4烷基）、N（C1-4烷基）2、OC（O）NR9R8、NR8C（O）R9或C（O）NR9R8；R9和R8独立地代表氢、C1-4烷基或C3-7环烷基；m代表零或1至4的整数；n代表1或2；p为零或1至3的整数；q为1至3的整数；r为1至4的整数；t为0、1或2；但当m为0，p为2，q、r和n均为1，R1、R2、R3、R4、R5和R7均为氢，R为氯时，R5不为碘；以及其药学上可接受的盐和溶剂化合物；其制备方法和在治疗由粘附素介导和/或选择性抑制血清素再摄取转运蛋白介导的疾病中的应用。
• Compounds, pharmaceutical compositions and methods of use therefor
  申请人：Ghosh Shomir

  公开号：US20050143372A1

  公开（公告）日：2005-06-30

  The invention relates to compounds having the formula (I). Preferred compounds are antagonists of C—C chemokine receptor 8. The invention also relates to a method for treating a subjected having an inflammatory disorder or viral disorder comprising administering to a subject in need thereof an effective amount of a compound of the invention.

  该发明涉及具有公式（I）的化合物。首选化合物是C-C趋化因子受体8的拮抗剂。该发明还涉及一种治疗患有炎症性疾病或病毒性疾病的受试者的方法，该方法包括向需要的受试者施用该发明的化合物的有效量。
• PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20100256126A1

  公开（公告）日：2010-10-07

  The present application relates to compounds of formula wherein the definitions are as described herein. The present compounds are high potential NK-3 receptor antagonists that are useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  本申请涉及以下式子的化合物，其中定义如本文所述。这些化合物是高潜力的NK-3受体拮抗剂，可用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑症和注意力缺陷多动障碍（ADHD）。